Effect of Canagliflozin (CANA) on Liver Function Tests (LFTs) in Patients with Type 2 Diabetes Mellitus (T2DM)

被引：0
|
作者：
Usiskin, Keith
Leiter, Lawrence A.
Forst, Thomas
Polidori, David
Xie, John
Sha, Sue
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1092-P
引用
收藏
页码：A284 / A284
页数：1
相关论文
共 50 条
  • [41] Time Until Insulin Initiation for Canagliflozin (CANA) vs. Sitagliptin (SITA) in Dual Therapy and Triple Therapy for Type 2 Diabetes Mellitus (T2DM) in the UK
    Schroeder, Melanie
    Chan, Edmond
    Willis, Michael
    Johansen, Pierre
    Nilsson, Andreas
    Schubert, Agata
    Neslusan, Cheryl
    [J]. DIABETES, 2016, 65 : A327 - A327
  • [42] Liver Fibrosis Is Common in Patients with Type 2 Diabetes Mellitus (T2DM) and Nonalcoholic Fatty Liver Disease (NAFLD)
    Lomonaco, Romina
    Fanous, Nada
    Kalavalapalli, Srilaxmi
    Tejera, Lazaro J.
    McCauley, Allison
    Godinez, Eddison
    Mansour, Lydia
    Shrestha, Sulav
    Marte, Jonathan S.
    Fakhry, Jonathan
    Wang, Hannah
    Barb, Diana
    Bril, Fernando
    Cusi, Kenneth
    [J]. DIABETES, 2020, 69
  • [43] In vitro effect of gliclazide on DNA damage and repair in patients with type 2 diabetes mellitus (T2DM)
    Sliwinska, Agnieszka
    Blasiak, Janusz
    Kasznicki, Jacek
    Drzewoski, Jozef
    [J]. CHEMICO-BIOLOGICAL INTERACTIONS, 2008, 173 (03) : 159 - 165
  • [44] Real-World Outcomes of Patients with Type 2 Diabetes Mellitus (T2DM) Treated with Canagliflozin in a US Managed Care Setting
    Chow, Wing
    Buysman, Erin K.
    Rupnow, Marcia F. T.
    Henk, Henry J.
    [J]. DIABETES, 2015, 64 : A347 - A348
  • [45] Cardiac Dysfunction in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) and Type 2 Diabetes Mellitus (T2DM)
    Zemlianitsyna, Olga
    Dunayeva, Inna
    Kravchun, Nonna
    Sinaiko, Vadym
    Lavrynenko, Olga
    DeFronzo, Ralph
    [J]. AMERICAN HEART JOURNAL, 2020, 229 : 158 - 159
  • [46] ASSESSMENT OF THE KEY DRIVERS OF COST-EFFECTIVENESS IN THE ECONOMIC MODELLING OF CANAGLIFLOZIN (CANA) VERSUS GLIMEPIRIDE (GLIM) IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN THE UK SETTING
    Thompson, G.
    Willis, M.
    Johansen, P.
    Neslusan, C.
    Schroeder, M.
    Girod, I
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A441 - A441
  • [47] Cause of Hospitalizations in Patients with Type 2 Diabetes Mellitus (T2DM) in the CANVAS Program
    Mahaffey, Kenneth W.
    Ianus, Juliana
    Damaraju, C. V.
    Neal, Bruce
    De Zeeuw, Dick
    Fulcher, Greg
    Pfeifer, Michael
    Matthews, David R.
    [J]. DIABETES, 2019, 68
  • [48] Inappropriate metformin prescribing in elderly type 2 diabetes mellitus (T2DM) patients
    Kosmalski, M.
    Drozdowska, A.
    Sliwinska, A.
    Drzewoski, J.
    [J]. ADVANCES IN MEDICAL SCIENCES, 2012, 57 (01): : 65 - 70
  • [49] MobiDiabet: Mobile Telemonitoring System for Patients with Type 2 Diabetes Mellitus (T2DM)
    Alcala Juarez, Anakaren
    Hernandez Villegas, Manuel Alejandro
    Dominguez, Eduardo Lopez
    Hernandez Velazquez, Yesenia
    Dominguez Isidro, Saul
    Ovando Diego, Liliana
    Hernandez Sanchez, Olivia
    De La Calleja, Jorge
    Pomares Hernandez, Saul Eduardo
    Medina Nieto, Maria Auxilio
    [J]. APPLIED SCIENCES-BASEL, 2020, 10 (22): : 1 - 36
  • [50] Efficacy of canagliflozin (CANA) in combination with metformin (MET) in patients with T2DM: Results from 3 studies
    Qiu, Rong
    Xie, John
    Hamilton, Gill
    Canovatchel, William
    Fegade, Mayuresh
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S118 - S118
12345